Incorporation of labelled N-acylethanolamine (NAE) into rat brain regions in vivo and adaptive properties of saturated NAE under x-ray irradiation.
Regional distribution of exogenous N-palmitoylethanolamine in the rat brain was investigated in the study. Possible protective and adaptive effect of N-stearoylethanolamine under 2 Gy whole-body X-irradiation and changes of brain lipid composition were also studied. It was found that after per os administration to rats N-([9,10-3H]-palmitoyl)-ethanolamine was primarily accumulated in hypothalamus, pituitary and adrenal glands and the label amount in brain was 0.95% of the oral dose. Quantities of palmitic acid in total brain phospholipids and plasmalogen form of phosphatidylcholine were increased; free cholesterol and diacyl form of phosphatidylcholine were decreased in 2 weeks after irradiation. 11-OH-corticosteroid level in the blood of exposed rats was decreased in comparison with control animals. N-stearoylethanolamine pre-treatment prevented from increasing the plasmalogen form of phosphatidylcholine and decreasing its diacyl form and restored 11-OH-corticosteroid level in the blood of irradiated rats. Recovering of brain free cholesterol level was observed when N-stearoylethanolamine was post-treated. So, the accumulation of N-([9,10-3H]-palmitoyl)ethanolamine in brain indicates its penetration through blood-brain barrier and suggests the possible role of saturated N-acylethanolamines in brain functioning, particularly, in stress response regulation of the organism by hypothalamus-pituitary-adrenal system. N-stearoylethanolamine treatment of irradiated rats causes protective effect concerning the of irradiation induced changes in the brain lipid composition and in 11-OH-corticosteroid level and modifies phospholipid fatty acid composition.
Artamonov
M
M
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv. artamon@biochem.kiev.ua
Zhukov
O
O
Shuba
I
I
Storozhuk
L
L
Khmel
T
T
Klimashevsky
V
V
Mikosha
A
A
Gula
N
N
D015062:11-Hydroxycorticosteroids / Q000378:metabolism; D000311:Adrenal Glands / Q000378:metabolism; D000577:Amides; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects*; D063388:Endocannabinoids; D004983:Ethanolamines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D009934:Organization and Administration; D010169:Palmitic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011833:Radiation Injuries, Experimental / Q000378:metabolism / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013229:Stearic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014916:Whole-Body Irradiation; D014965:X-Rays / Q000009:adverse effects
D015062:11-Hydroxycorticosteroids; D000577:Amides; D063388:Endocannabinoids; D004983:Ethanolamines; C408368:N-stearoylethanolamine; D010169:Palmitic Acids; D011837:Radiation-Protective Agents; D013229:Stearic Acids; C005958:palmidrol